NAMS newamsterdampharma.com Net earnings per share for the last 12 months

NewAmsterdam Pharma revenues are based on the market launch of the innovative Obicetrapib for cholesterol management. This 12-month net income per share chart visualizes this trajectory, where the value of -1.71 reflects this status. The company's strategy relies on creating an affordable oral alternative to injections. Minimal geopolitical influence on the biopharmaceutical sector supports the business's stability.
Analytical breakdowns and data insights for company NewAmsterdam Pharma Corp (NAMS)

This indicator determines the equity value of the asset by calculating the aggregate net income over four quarters per ordinary share. The annual net income per share trend reflects capital management efficiency, while the current negative trend for NewAmsterdam Pharma (NAMS) is driven by development costs for a cholesterol drug, which is standard prior to the commercialization stage.